T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy

Bibliography

• ROSENBERG SA, AEBERSOLD P, CORNETTA K et al.: Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 323(9):570-578.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANNELLI JR, YANG JC et al.: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 86(15):1159-1166.
   PubMed Web of Science ®Google Scholar
• KOLB HJ, MITTERMULLER J, CLEMM C et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 76(12):2462-2465.
   PubMed Web of Science ®Google Scholar
• PORTER DL, COLLINS RH, JR., HARDY C et al.: Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood (2000) 95(4):1214-1221.
   PubMed Web of Science ®Google Scholar
• ROONEY CM, SMITH CA, NG CY et al.: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 345(8941):9-13.
   PubMed Web of Science ®Google Scholar
• WALTER EA, GREENBERG PD, GILBERT MJ et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 333(16):1038-1044.
   PubMed Web of Science ®Google Scholar
• RIDDELL SR, GILBERT MJ, GREENBERG PD: CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection. Curr Opin Immunol (1993) 5(4):484-491.
   PubMed Web of Science ®Google Scholar
• RIDDELL SR, WATANABE KS, GOODRICH JM et al.: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 257(5067):238-241.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-854.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, RESTIFO NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 10(9):909-915.
   PubMed Web of Science ®Google Scholar
• POWELL DJ, JR., DUDLEY ME, HOGAN KA, WUNDERLICH JR, ROSENBERG SA: Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol (2006) 177(9):6527-6539.
   PubMed Web of Science ®Google Scholar
• KLEBANOFF CA, KHONG HT, ANTONY PA, PALMER DC, RESTIFO NP: Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 26(2):111-117.
   PubMed Web of Science ®Google Scholar
• ROBBINS PF, DUDLEY ME, WUNDERLICH J et al.: Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 173(12):7125-7130.
   PubMed Web of Science ®Google Scholar
• GATTINONI L, KLEBANOFF CA, PALMER DC et al.: Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 115(6):1616-1626.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, YANG JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 23(10):2346-2357.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, DUDLEY ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad SciUSA (2004) 101 Suppl. 2:14639-14645.
   PubMed Web of Science ®Google Scholar
• CROWLEY NJ, SLINGLUFF CL, JR., DARROW TL, SEIGLER HF: Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res (1990) 50(3):492-498.
   PubMed Web of Science ®Google Scholar
• MANDRUZZATO S, ROSSI E, BERNARDI F et al.: Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. J Immunol (2002) 169(7):4017-4024.
   PubMed Web of Science ®Google Scholar
• STEVENS EJ, JACKNIN L, ROBBINS PF et al.: Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J Immunol (1995) 154(2):762-771.
   PubMed Web of Science ®Google Scholar
• WANG LX, HUANG WX, GRAOR H et al.: Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med (2004) 2(1):41.
   Google Scholar
• DEMBIC Z, HAAS W, WEISS S et al.: Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature (1986) 320(6059):232-238.
   PubMed Web of Science ®Google Scholar
• BLAESE RM, CULVER KW, MILLER AD et al.: T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 270(5235):475-480.
   PubMed Web of Science ®Google Scholar
• BORDIGNON C, NOTARANGELO LD, NOBILI N et al.: Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 270(5235):470-475.
   PubMed Web of Science ®Google Scholar
• FISCHER A, HACEIN-BEY S, CAVAZZANA-CALVO M: Gene therapy of severe combined immunodeficiencies. Nat Rev Immunol (2002) 2(8):615-621.
   PubMed Web of Science ®Google Scholar
• RIDDELL SR, GREENBERG PD: Principles for adoptive T cell therapy of human viral diseases. Ann. Rev Immunol (1995) 13:545-586.
   PubMed Web of Science ®Google Scholar
• HWU P, YANNELLI J, KRIEGLER M et al.: Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J Immunol (1993) 150(9):4104-4115.
   PubMed Web of Science ®Google Scholar
• SADELAIN M, RIVIERE I, BRENTJENS R: Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 3(1):35-45.
   PubMed Web of Science ®Google Scholar
• BORDIGNON C, BONINI C, VERZELETTI S et al.: Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther (1995) 6(6):813-819.
   PubMed Web of Science ®Google Scholar
• SCHUMACHER TN: T-cell-receptor gene therapy. Nat Rev Immunol (2002) 2(7):512-519.
   PubMed Web of Science ®Google Scholar
• THISTLETHWAITE F, MANSOOR W, GILHAM DE, HAWKINS RE: Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther (2005) 7(1):48-55.
   PubMed Web of Science ®Google Scholar
• KERSHAW MH, WESTWOOD JA, PARKER LL et al.: A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 12(20 Pt 1):6106-6115.
   PubMed Web of Science ®Google Scholar
• MORGAN RA, DUDLEY ME, WUNDERLICH JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314(5796):126-129.
   PubMed Web of Science ®Google Scholar
• CLAY TM, CUSTER MC, SACHS J et al.: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol (1999) 163(1):507-513.
   PubMed Web of Science ®Google Scholar
• MORGAN RA, DUDLEY ME, YU YY et al.: High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol (2003) 171(6):3287-3295.
   PubMed Web of Science ®Google Scholar
• ORENTAS RJ, ROSKOPF SJ, NOLAN GP, NISHIMURA MI: Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin Immunol (2001) 98(2):220-228.
   PubMed Web of Science ®Google Scholar
• ROSZKOWSKI JJ, LYONS GE, KAST WM et al.: Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res (2005) 65(4):1570-1576.
   PubMed Web of Science ®Google Scholar
• TSUJI T, YASUKAWA M, MATSUZAKI J et al.: Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood (2005) 106(2):470-476.
   PubMed Web of Science ®Google Scholar
• ZHAO Y, ZHENG Z, ROBBINS PF et al.: Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol (2005) 174(7):4415-4423.
   PubMed Web of Science ®Google Scholar
• FUJIO K, MISAKI Y, SETOGUCHI K et al.: Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol (2000) 165(1):528-532.
   PubMed Web of Science ®Google Scholar
• SCHAFT N, WILLEMSEN RA, DE VRIES J et al.: Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol (2003) 170(4):2186-2194.
   PubMed Web of Science ®Google Scholar
• HEEMSKERK MH, HOOGEBOOM M, HAGEDOORN R et al.: Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med (2004) 199(7):885-894.
   PubMed Web of Science ®Google Scholar
• KESSELS HW, WOLKERS MC, VAN DEN BOOM MD, VAN DER VALK MA, SCHUMACHER TN: Immunotherapy through TCR gene transfer. Nat Immunol (2001) 2(10):957-961.
   PubMed Web of Science ®Google Scholar
• CHAMOTO K, TSUJI T, FUNAMOTO H et al.: Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper Type 1 cells. Cancer Res (2004) 64(1):386-390.
   PubMed Web of Science ®Google Scholar
• DE WITTE MA, COCCORIS M, WOLKERS MC et al.: Targeting self-antigens through allogeneic TCR gene transfer. Blood (2006) 108(3):870-877.
   PubMed Web of Science ®Google Scholar
• TAHARA H, FUJIO K, ARAKI Y et al.: Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte. J Immunol (2003) 171(4):2154-2160.
   PubMed Web of Science ®Google Scholar
• COHEN CJ, ZHENG Z, BRAY R et al.: Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol (2005) 175(9):5799-5808.
   PubMed Web of Science ®Google Scholar
• KUBALL J, SCHMITZ FW, VOSS RH et al.: Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 22(1):117-129.
   Google Scholar
• LI Y, MOYSEY R, MOLLOY PE et al.: Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol (2005) 23(3):349-354.
   PubMed Web of Science ®Google Scholar
• STANISLAWSKI T, VOSS RH, LOTZ C et al.: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2(10):962-970.
   PubMed Web of Science ®Google Scholar
• AIUTI A, SLAVIN S, AKER M et al.: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 296(5577):2410-2413.
   PubMed Web of Science ®Google Scholar
• HACEIN-BEY-ABINA S, LE DEIST F, CARLIER F et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med (2002) 346(16):1185-1193.
   PubMed Web of Science ®Google Scholar
• ENGELS B, UCKERT W: Redirecting T lymphocyte specificity by T cell receptor gene transfer – A new era for immunotherapy. Mol Aspects Med (2007) 28(1):115-142.
   PubMed Web of Science ®Google Scholar
• FOLLENZI A, BATTAGLIA M, LOMBARDO A et al.: Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic Factor IX in mice. Blood (2004) 103(10):3700-3709.
   PubMed Web of Science ®Google Scholar
• KORDOWER JH, EMBORG ME, BLOCH J et al.: Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science (2000) 290(5492):767-773.
   PubMed Web of Science ®Google Scholar
• MIYOSHI H, SMITH KA, MOSIER DE, VERMA IM, TORBETT BE: Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 283(5402):682-686.
   PubMed Web of Science ®Google Scholar
• NALDINI L, BLOMER U, GALLAY P et al.: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272(5259):263-267.
   PubMed Web of Science ®Google Scholar
• NGUYEN TH, OBERHOLZER J, BIRRAUX J et al.: Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol Ther (2002) 6(2):199-209.
   PubMed Web of Science ®Google Scholar
• KAFRI T, BLOMER U, PETERSON DA, GAGE FH, VERMA IM: Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet (1997) 17(3):314-317.
   PubMed Web of Science ®Google Scholar
• FOLLENZI A, AILLES, L.E., BAKOVIC, S., GEUNA, M., AND NALDINI, L.: Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. (2000) 25:217-222.
   PubMed Web of Science ®Google Scholar
• ZUFFEREY R, DONELLO JE, TRONO D, HOPE TJ: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol (1999) 73(4):2886-2892.
   PubMed Web of Science ®Google Scholar
• DARDALHON V, HERPERS B, NORAZ N et al.: Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther (2001) 8(3):190-198.
   PubMed Web of Science ®Google Scholar
• ZENNOU V, PETIT C, GUETARD D et al.: HIV-1 genome nuclear import is mediated by a central DNA flap. Cell (2000) 101(2):173-185.
   PubMed Web of Science ®Google Scholar
• VIGNA E, NALDINI L: Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med (2000) 2(5):308-316.
   PubMed Web of Science ®Google Scholar
• HEMATTI P, HONG BK, FERGUSON C et al.: Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol (2004) 2(12):e423.
   PubMedGoogle Scholar
• LAUFS S, GENTNER B, NAGY KZ et al.: Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood (2003) 101(6):2191-2198.
   PubMed Web of Science ®Google Scholar
• MITCHELL RS, BEITZEL BF, SCHRODER AR et al.: Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol (2004) 2(8):E234.
   PubMedGoogle Scholar
• SCHRODER AR, SHINN P, CHEN H et al.: HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 110(4):521-529.
   PubMed Web of Science ®Google Scholar
• HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302(5644):415-419.
   PubMed Web of Science ®Google Scholar
• ZAISS AK, SON S, CHANG LJ: RNA 3’ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol (2002) 76(14):7209-7219.
   PubMed Web of Science ®Google Scholar
• CHUN TW, CARRUTH L, FINZI D et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 387(6629):183-188.
   PubMed Web of Science ®Google Scholar
• HERNDIER BG, SHIRAMIZU BT, JEWETT NE et al.: Acquired immunodeficiency syndrome-associated T-cell lymphoma: evidence for human immunodeficiency virus Type 1-associated T-cell transformation. Blood (1992) 79(7):1768-1774.
   PubMed Web of Science ®Google Scholar
• ROUZINE IMAC, J.M.: Search for the Mechanism of Genetic Variation in the pro Gene of Human Immunodeficiency Virus. Journal of Virology (1999) 73(10):8167-8178.
   PubMed Web of Science ®Google Scholar
• MONTINI E, CESANA D, SCHMIDT M et al.: Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 24(6):687-696.
   PubMed Web of Science ®Google Scholar
• MACGREGOR RR: Clinical protocol. A Phase I open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum Gene Ther (2001) 12(16):2028-2029.
   PubMedGoogle Scholar
• LU X, HUMEAU L, SLEPUSHKIN V et al.: Safe two-plasmid production for the first clinical lentivirus vector that achieves > 99% transduction in primary cells using a one-step protocol. J Gene Med (2004) 6(9):963-973.
   PubMed Web of Science ®Google Scholar
• HUMEAU LM, BINDER GK, LU X et al.: Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther (2004) 9(6):902-913.
   PubMed Web of Science ®Google Scholar
• LEVINE BL, HUMEAU LM, BOYER J et al.: Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad SciUSA (2006) 103(46):17372-17377.
   PubMed Web of Science ®Google Scholar
• GEGINAT J, LANZAVECCHIA A, SALLUSTO F: Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood (2003) 101(11):4260-4266.
   PubMed Web of Science ®Google Scholar
• GEGINAT J, SALLUSTO F, LANZAVECCHIA A: Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med (2001) 194(12):1711-1719.
   PubMed Web of Science ®Google Scholar
• DROBYSKI WR, MAJEWSKI D, OZKER K, HANSON G: Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. J Immunol (1998) 161(5):2610-2619.
   PubMed Web of Science ®Google Scholar
• FERRAND C, ROBINET E, CONTASSOT E et al.: Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum Gene Ther (2000) 11(8):1151-1164.
   PubMed Web of Science ®Google Scholar
• SAUCE D, BODINIER M, GARIN M et al.: Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood (2002) 99(4):1165-1173.
   PubMed Web of Science ®Google Scholar
• GATTINONI L, POWELL DJ, JR., ROSENBERG SA, RESTIFO NP: Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 6(5):383-393.
   PubMed Web of Science ®Google Scholar
• LANZAVECCHIA A, SALLUSTO F: Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol (2002) 2(12):982-987.
   PubMed Web of Science ®Google Scholar
• JU ST, PANKA DJ, CUI H et al.: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (1995) 373(6513):444-448.
   PubMed Web of Science ®Google Scholar
• CONTASSOT E, MURPHY W, ANGONIN R et al.: In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes. Transplantation (1998) 65(10):1365-1370.
   PubMed Web of Science ®Google Scholar
• MARKTEL S, MAGNANI Z, CICERI F et al.: Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood (2003) 101(4):1290-1298.
   PubMed Web of Science ®Google Scholar
• GAO Z, GOLOB J, TANAVDE VM et al.: High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector. Stem Cells (2001) 19(3):247-259.
   PubMed Web of Science ®Google Scholar
• COSTELLO E, MUNOZ M, BUETTI E et al.: Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther (2000) 7(7):596-604.
   PubMed Web of Science ®Google Scholar
• ZHOU X, CUI Y, HUANG X et al.: Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther (2003) 14(11):1089-1105.
   PubMed Web of Science ®Google Scholar
• LOTTI F, MENGUZZATO E, ROSSI C et al.: Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement. J Virol (2002) 76(8):3996-4007.
   PubMed Web of Science ®Google Scholar
• VIGNA E, CAVALIERI S, AILLES L et al.: Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther (2002) 5(3):252-261.
   PubMed Web of Science ®Google Scholar
• AUTEN J, AGARWAL M, CHEN J, SUTTON R, PLAVEC I: Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum Gene Ther (1999) 10(8):1389-1399.
   PubMed Web of Science ®Google Scholar
• PARKMAN R, WEINBERG K, CROOKS G et al.: Gene therapy for adenosine deaminase deficiency. Ann. Rev Med (2000) 51:33-47.
   PubMed Web of Science ®Google Scholar
• PLAVEC I, AGARWAL M, HO KE et al.: High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Ther (1997) 4(2):128-139.
   PubMed Web of Science ®Google Scholar
• TONG-STARKSEN SE WT, PETERLIN BM Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals. J Immunol (1990) 15:4348-4354.
   Google Scholar
• DUPRE L, TRIFARI S, FOLLENZI A et al.: Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther (2004) 10(5):903-915.
   PubMed Web of Science ®Google Scholar
• CAVALIERI S, CAZZANIGA S, GEUNA M et al.: Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood (2003) 102(2):497-505.
   PubMed Web of Science ®Google Scholar
• AMENDOLA M, VENNERI, M.A., BIFFI, A., VIGNA, E., NALDINI, L.: Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol (2005) 23:108-116.
   PubMed Web of Science ®Google Scholar
• CLAY TM, CUSTER MC, SPIESS PJ, NISHIMURA MI: Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Pathol Oncol Res (1999) 5(1):3-15.
   PubMedGoogle Scholar
• PFEIFER A, IKAWA M, DAYN Y, VERMA IM: Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad SciUSA (2002) 99(4):2140-2145.
   PubMed Web of Science ®Google Scholar
• SINN PL, SAUTER SL, MCCRAY PB, JR.: Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther (2005) 12(14):1089-1098.
   PubMed Web of Science ®Google Scholar
• BAXEVANIS CN, VOUTSAS IF, TSITSILONIS OE et al.: Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol (2000) 164(7):3902-3912.
   PubMed Web of Science ®Google Scholar
• HO WY, YEE C, GREENBERG PD: Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest (2002) 110(10):1415-1417.
   PubMed Web of Science ®Google Scholar
• SHEDLOCK DJ, SHEN H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 300(5617):337-339.
   PubMed Web of Science ®Google Scholar
• SURMAN DR, DUDLEY ME, OVERWIJK WW, RESTIFO NP: Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol (2000) 164(2):562-565.
   PubMed Web of Science ®Google Scholar
• ANTONY PA, PICCIRILLO CA, AKPINARLI A et al.: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 174(5):2591-2601.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH J, NISHIMURA MI et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 24(4):363-373.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, YANG JC et al.: A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 25(3):243-251.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, TOULOUKIAN CE, YANG JC et al.: Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother (2003) 26(4):349-356.
   PubMed Web of Science ®Google Scholar
• SCHOLTEN KB, KRAMER D, KUETER EW et al.: Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol (2006) 119(2):135-145.
   PubMed Web of Science ®Google Scholar
• SCHUMACHER TN: T-Cell-Receptor gene transfer. Nat Rev Immunol (2002) 2
   PubMedGoogle Scholar
• BOLLARD CM, KUEHNLE I, LEEN A, ROONEY CM, HESLOP HE: Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant (2004) 10(3):143-155.
   PubMed Web of Science ®Google Scholar
• VAN DER VEKEN LT, HAGEDOORN RS, VAN LOENEN MM et al.: Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res (2006) 66(6):3331-3337.
   PubMed Web of Science ®Google Scholar
• GORDON JD, VONDERHEIDE, R.H.: Universal Tumor Antigens as Targets for Immunotherapy. Cytotherapy (2002) 4:317-327.
   PubMed Web of Science ®Google Scholar